Our Science

Transformative Potential of Allostery

Approximately 90% of disease-causing proteins are not drugged, or are inadequately drugged due to limitations with traditional small molecules that target the active site of a protein.

Atavistik leverages allostery to identify novel opportunities for therapeutic intervention and develop differentiated medicines that target the underlying biology of disease.

By leveraging our novel allosteric drug discovery platform, we are advancing a pipeline of hematology therapeutics designed to address significant unmet medical needs, including hereditary hemorrhagic telanglectasia (HHT).

pie chart

———

Harnessing Allostery to Address the Underlying Biology of Disease

We are harnessing the power of allostery to address unmet patient needs.

diagram

Allostery enables novel approaches to challenging disease-driving targets.

diagram

Our platform identifies biologically relevant allosteric binding sites that can support the development of highly selective therapeutics.

diagram

The discovery of novel allosteric binding sites enables the efficient development of differentiated therapies with the potential to address significant unmet medical needs. 

diagram

By leveraging the body’s natural regulators, we efficiently and systematically uncover functional allosteric pockets across a broad range of target classes (e.g., transcription factors, membrane proteins, large complexes).

Our Platform

Our platform identifies novel allosteric binding sites that enable the discovery and development of differentiated hematology therapeutics.

Atavistik platform diagram 1 right arrow Atavistik platform diagram 2 right arrow Atavistik platform diagram 2
Proprietary AMPS screening technology repeatedly identifies functional allosteric binders Novel cryptic binding pockets enable rapid and efficient AI/ML driven structure-based drug design and chemistry Structure-based drug design supports rapid improvements in potency to generate differentiated therapeutics

Therapeutic Approach

Our allosteric development platform supports the discovery of differentiated therapeutic approaches against challenging disease-driving targets. Insights generated through the platform have enabled the advancement of our internal pipeline focused on rare hematologic diseases, including hereditary hemorrhagic telangiectasia (HHT).

Beyond our internal programs, we believe the broad applicability of allosteric biology creates opportunities for strategic partnerships aimed at advancing innovative therapies across additional therapeutic areas.